July 17, 2012 – According to an order issued earlier this week, it will be more than two years before the first federal Actos bladder cancer lawsuits go to trial. Last December, the Actos multidistrict litigation (MDL) was centralized before U.S. District Judge Rebecca Doherty in the Western District of Louisiana for consolidated handling during pretrial proceedings. Over the past two years, concerns have emerged about the risk of Actos, after studies were conducted which linked the drug to an increased risk for bladder cancer.
Actos Bladder Cancer Lawsuit Update April 8, 2014: In the first U.S. trial of its kind, Takeda Pharmaceuticals and Eli Lilly were ordered to pay a total of $9 billion in punitive damages after a jury agreed that the companies failed to warn the public and medical communities about the bladder cancer risk associated with their controversial type 2 diabetes drug Actos (pioglitazone). The lawsuit claimed that Takeda and Lilly downplayed or ignored concerns about Actos’ link to bladder cancer, and mislead health authorities in order to protect profits. Click here to learn more.
Free Actos Lawsuit Evaluation: If you or a loved one has been injured by Actos, you should contact our law firm immediately. You may be entitled to compensation by filing a suit against the manufacturer of Actos and we can help.
What’s the problem?
On Friday, Judge Doherty outlined a schedule for the Actos MDL, which will culminate with the first bellwether trial date in November 2014, and a second in January 2015. Bellwether cases are common in complex pharmaceutical litigation, where a large number of lawsuits have been filed involving similar allegations. The outcome of these early trials is intended to allow parties to gauge how juries are likely to respond to evidence that is going to be presented in multiple cases.
The tentative protocol for the litigation is as follows:
- The Court will issue an order describing the bellwether trial process by October 31, 2012;
- Each party will then select 20 cases by June 3, 2013, to be prepared for the first trial dates;
- Core discovery in the bellwether cases is expected to be completed by September 30, 2013;
- Selection of the cases to be presented during the first bellwether trials will be made by October 16, 2013;
- The first trial date will begin on November 3, 2014, and the second trial date is set to begin January 12, 2015.
To date, hundreds of Actos bladder cancer lawsuits have been filed in courthouses around the country, and industry insiders expect the litigation to grow exponentially until the MDL begins. While the statute of limitations for Actos cases arising in states with a one year limitation period may expire next month, the vast majority of states allow injured parties two or three years to file their claim. Therefore, the volume of new cases is unlikely to diminish in the near future.
First approved by the U.S. Food & Drug Administration (FDA) in July 1999, Actos (generic: pioglitazone) is a once-a-day type-2 diabetes drug designed to increase the body’s sensitivity to insulin. In June 2011, the administration issued a press release stating that new information regarding the risk of bladder cancer would be added to Actos warning labels. Although Actos was recalled in France over bladder cancer concerns, the FDA has not indicated that a recall for Actos will be issued here at home in the United States.
Do I Have an Actos Lawsuit?
The Product Liability & Defective Drug Litigation Group at our law firm is an experienced team of trial lawyers that focus on the representation of plaintiffs in Actos lawsuits. We are handling individual litigation nationwide and currently accepting new side effects cases in all 50 states.
Free Actos Lawsuit Evaluation: If you or a loved one has been injured by Actos, you should contact our law firm immediately. You may be entitled to compensation by filing an Actos injury suit and we can help.